PBAC's latest decision on Peginterferon alfa-2a: Recommended with restriction (2017). Considered for Chronic hepatitis B and C infections; also proposed for use in myeloproliferative neoplasms (essential thrombocythemia and polycythemia vera).
PBAC outcome
Recommended with restriction
Unrestricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
2
first 2005
Submissions
2
2005 → 2017
Eligible population
Patients with chronic hepatitis B and C, and patients with myeloproliferative neoplasms (essential thrombocythemia and polycythemia vera) unable to be treated with hydroxyurea.
Therapy area
Infectious disease
Line of therapy
Not applicable
Evidence base
RCT
Economic model
BIA only
ICER note
Not modelled — this was a minor submission (change of authority level only) with no economic evaluation or ICER calculation.
ICER (historical)
$15k/QALY–$45k/QALY in an earlier submission (2005) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
Risk sharing
Risk-sharing arrangement in place — Proposed subsidisation cap on PBS expenditure to limit financial risk to the Commonwealth associated with use in MPN and chronic hepatitis B and C.
Submission history
Nov 2005: Recommended with restriction · Authority Required — ICER $45k/QALY
Nov 2017: Recommended with restriction · Unrestricted